Recent studies suggest the use of K18 and cK18 as biomarkers in the diagnosis of NAFLD and NASH [75,78,79], as well as in the monitoring of patients, in response to treatment [80,81]. This evidence concerns the gene KRT18 and metabolic dysfunction-associated steatotic liver disease.